Despite high response rates, disease progression after anti-CD30 CAR T-cells is frequent, and treatment failures have been mainly correlated to a high value of metabolic tumor volume by PET scan performed before CAR T-cell infusion [154]. The gene discussed is TNFRSF8; the disease is neoplasm.